GAD2 and type 1 diabetes mellitus: Some of the reviewed interventions encompass a wide range of approaches, including the use of broad immunosuppressants to exhaust and alter T-cell phenotype (see Fig. 4 and section Pharmaceutically induced T-cell blockade leading to partial or full exhaustion), the inhibition of specific cytokines associated with T1D progression (see section Pharmaceutical inhibition of cytokines and corresponding receptors), and the modulation of immunity by enhancing immunologic tolerance (see section Modifying immunity through autoantigens: GAD65 Alum).